Indeed, a phase I/II clinical trial of for the dual treatment of patients with BRAF-positive advanced melanoma with BKM120, a PI3K inhibitor, and vemurafenib had been initiated, although terminated early due to therapy-related toxicity (NCT01512251). This evidence concerns the gene BRAF and melanoma.